This dual-drug therapy aims to enhance vessel patency and prevent restenosis. Credit: Advanced NanoTherapies / PRNewswire.

Advanced NanoTherapies (ANT) has reported positive outcomes from its first-in-human (FIH) trial of the SirPlux Duo Drug-Coated Balloon (DCB).  

The company is preparing to launch an early feasibility study in the US to further evaluate the performance and safety of this treatment for de novo coronary lesions. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

SirPlux Duo DCB is a new therapy that simultaneously delivers sirolimus and paclitaxel, two drugs known for their efficacy in inhibiting cell growth.  

This dual-drug therapy aims to enhance vessel patency and prevent restenosis. 

ANT co-founder and CEO Marwan Berrada-Sounni said: “We are thrilled to take this next step in further validating the clinical performance of SirPlux Duo DCB, a novel technology licensed from the Cleveland Clinic.” 

“Moving forward with our DYNAMIC DUO I EFS aligns with our vision of advancing nanotechnology-driven solutions that combine the power of sirolimus and paclitaxel to offer a safe and prolonged therapy without leaving a permanent implant behind.” 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ANT’s nanoparticle drug encapsulation platform facilitates safe and sustained long-term bioavailability of both drugs within the tissue, without the need for a stent.  

The upcoming DYNAMIC DUO I early feasibility study (EFS) is a prospective, multi-centre, non-randomised trial targeting patients with symptomatic stable angina, unstable angina, or NSTEMI who have de novo coronary lesions with reference vessel diameters between two and four millimetres. 

The results of this study are expected to guide ANT in expanding its clinical programmes towards broader commercialisation in both the US and international markets.  

In August 2023, the company secured a $4m Series A extension from a strategic medical device company.  

Additionally, ANT successfully treated its first group of participants in the ADVANCE-DCB FIH trial, showcasing initial short-term safety data for the SirPlux Duo DCB in treating de novo coronary artery disease (CAD).